journal article·2021-08-27

Optically Activatable Double-Drug-Loaded Perfluorocarbon Nanodroplets for On-Demand Image-Guided Drug Delivery

Catalina-Paula Spatarelu, Austin Van Namen, Geoffrey P. Luke

ACS Applied Nano Materials· Volume 4· Issue 8
Publisher page

Abstract

Phase-changing nanodroplets have been studied as externally activatable in situ microbubble precursors. The nanodroplets can be triggered to vaporize with an external optical or acoustic energy source, and the resulting microbubbles can be visualized with high sensitivity using ultrasound imaging. Because of their nanoscale size, this type of construct is attractive for the encapsulation and on-site, on-demand release of therapeutics. Here, we develop a double-drug loaded nanodroplet platform that can coencapsulate paclitaxel and doxorubicin, and release them upon external laser activation. Nanodroplets are characterized in terms of size, stability, protein interaction, and drug release. Their capacity to concurrently release the two drugs and generate ultrasound contrast is demonstrated in vitro. The efficacy of dual-drug loaded nanodroplets is compared in vitro with that of free drug formulations, and potential mechanisms of their enhanced cytotoxic behavior are explored. Overall, the results show that the nanodroplets are a versatile platform for on-demand image-guided drug delivery.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Ultrasound and Hyperthermia Applications · Photoacoustic and Ultrasonic Imaging · Ultrasound and Cavitation Phenomena

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Thayer School of Engineering, Dartmouth College, Hanover, New Hampshire 03755, United States

Translational Engineering in Cancer Research Program, Norris Cotton Cancer Center, Lebanon, New Hampshire 03766, United States

Funding

Norris Cotton Cancer Center · NIH NIGMS · NCI Cancer Center Support Grant · NIH

References (61)

Show source-provided references
1. 10.1038/natrevmats.2017.2410.1038/natrevmats.2017.24 ↗
2. 10.1002/wnan.124710.1002/wnan.1247 ↗
3. 10.1021/mp100228v10.1021/mp100228v ↗
4. 10.1016/j.euje.2004.02.00110.1016/j.euje.2004.02.001 ↗
5. 10.2174/138920101466613122611461110.2174/1389201014666131226114611 ↗
6. 10.14366/usg.1702110.14366/usg.17021 ↗
7. 10.2174/13816121280009990010.2174/138161212800099900 ↗
8. 10.1016/j.jconrel.2009.05.02610.1016/j.jconrel.2009.05.026 ↗
9. 10.4236/jbnb.2011.22507510.4236/jbnb.2011.225075 ↗
10. 10.1002/wnan.117610.1002/wnan.1176 ↗
11. 10.1007/s10456-010-9166-010.1007/s10456-010-9166-0 ↗
12. 10.1016/j.acra.2011.04.01210.1016/j.acra.2011.04.012 ↗
13. 10.1124/jpet.118.25466410.1124/jpet.118.254664 ↗
14. 10.1007/s00424-020-02482-210.1007/s00424-020-02482-2 ↗
15. 10.1016/S0301-5629(00)00363-X10.1016/S0301-5629(00)00363-X ↗
16. 10.1016/j.biomaterials.2020.12030710.1016/j.biomaterials.2020.120307 ↗
17. 10.1002/nbm.305910.1002/nbm.3059 ↗
18. 10.1007/s00421-019-04252-010.1007/s00421-019-04252-0 ↗
19. 10.1023/A:102735591334810.1023/A:1027355913348 ↗
20. 10.1016/S0022-1139(00)84993-310.1016/S0022-1139(00)84993-3 ↗
21. 10.3109/1073119940913881210.3109/10731199409138812 ↗
22. 10.1155/2014/57968410.1155/2014/579684 ↗
23. 10.2174/13816121280009988310.2174/138161212800099883 ↗
24. 10.1364/BOE.9.00452710.1364/BOE.9.004527 ↗
25. 10.1016/j.jconrel.2018.11.02810.1016/j.jconrel.2018.11.028 ↗
26. 10.1121/1.338506710.1121/1.3385067 ↗
27. 10.1186/2050-5736-1-1110.1186/2050-5736-1-11 ↗
28. 10.1016/j.addr.2015.10.02210.1016/j.addr.2015.10.022 ↗
29. 10.1038/nrd268310.1038/nrd2683 ↗
30. 10.18632/oncotarget.1672310.18632/oncotarget.16723 ↗
31. 10.1124/mi.7.4.810.1124/mi.7.4.8 ↗
32. 10.1016/j.jconrel.2012.05.04510.1016/j.jconrel.2012.05.045 ↗
33. 10.1016/j.jconrel.2016.06.03710.1016/j.jconrel.2016.06.037 ↗
34. 10.1007/978-3-319-22536-4_1310.1007/978-3-319-22536-4_13 ↗
35. 10.1016/j.bcp.2012.01.00810.1016/j.bcp.2012.01.008 ↗
36. 10.1200/JCO.2008.19.256710.1200/JCO.2008.19.2567 ↗
37. 10.1088/0031-9155/52/20/N0210.1088/0031-9155/52/20/N02 ↗
38. DAPI Counterstaining Protocols; ThermoFisher Scientific, 2006. https://www.thermofisher.com/us/en/home/references/protocols/cell-and-tissue-analysis/dapi-protocol/basic-dapi-counterstaining-protocols.html
39. CellMask Deep Red Plasma membrane Stain https://www.thermofisher.com/order/catalog/product/C10046#/C10046 (accessed Feb 24, 2021).
40. 10.2174/13816121079192049610.2174/138161210791920496 ↗
41. 10.1002/cncr.1091410.1002/cncr.10914 ↗
42. 10.1016/j.canlet.2004.09.00710.1016/j.canlet.2004.09.007 ↗
43. 10.1021/acs.langmuir.9b0364710.1021/acs.langmuir.9b03647 ↗
44. 10.1016/j.colsurfb.2014.09.00910.1016/j.colsurfb.2014.09.009 ↗
45. 10.3390/pharmaceutics1106027910.3390/pharmaceutics11060279 ↗
46. 10.1016/j.jconrel.2011.09.06810.1016/j.jconrel.2011.09.068 ↗
47. 10.1016/j.ultsonch.2018.02.00410.1016/j.ultsonch.2018.02.004 ↗
48. 10.1016/j.ultrasmedbio.2021.02.01910.1016/j.ultrasmedbio.2021.02.019 ↗
49. 10.1007/s12274-019-2279-x10.1007/s12274-019-2279-x ↗
50. Airoldi M. · Anticancer Res. · 2008 · 28 · 2519
51. Bockstein B. · UpToDate · 2021
52. 10.1097/FPC.0b013e32833ffb5610.1097/FPC.0b013e32833ffb56 ↗
53. 10.1038/s41598-018-22056-810.1038/s41598-018-22056-8 ↗
54. 10.1038/srep2475310.1038/srep24753 ↗
55. 10.2147/NDT.S7818210.2147/NDT.S78182 ↗
56. 10.1109/TUFFC.2021.309382810.1109/TUFFC.2021.3093828 ↗
57. 10.1016/j.jconrel.2016.11.01510.1016/j.jconrel.2016.11.015 ↗
58. 10.1038/srep4407710.1038/srep44077 ↗
59. 10.1039/C7RA08971F10.1039/C7RA08971F ↗
60. 10.3389/fbioe.2019.0032410.3389/fbioe.2019.00324 ↗
61. 10.1117/12.254233910.1117/12.2542339 ↗